Work

Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy

Year: 2024

Type: article

Study design: Case Report

Source: Cancer Cell

DOI: 10.1016/j.ccell.2024.08.004

Authors: Christopher A. Eide, Diana Brewer, Tao Xie, Anna Reister Schultz, Samantha L. Savage, Serena Muratcioglu, Noah Merz, Richard D. Press, Thomas O’Hare, Thomas Jacob, Tania Q. Vu, Cristina E. Tognon, Tara A. Macey, John Kuriyan, Charalampos G. Kalodimos, Brian J. Druker

Institutions: Oregon Health & Science University, OHSU Knight Cancer Institute, St. Jude Children's Research Hospital, Vanderbilt University, Vanderbilt University Medical Center, University of Utah, Huntsman Cancer Institute

Language: English

Topic: Chronic Myeloid Leukemia Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Bristol-Myers Squibb, Pfizer, Iterion Therapeutics, National Institutes of Health, National Cancer Institute, National Institute of General Medical Sciences

Awards: Molecular Digital CytoImaging for Leukemia Drug Screening, Characterizing the landscape of resistance and persistence mechanisms in CML, G7704378018, Structure and functional mechanisms of molecular chaperones and protein kinases

OpenAlex ID: W4401992018

FWCI: 5.869

Cites: 12

Cited by: 19

Related to: 10